Bon Health vs NovoCare Pharmacy
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Bon Health
Best for shoppers wanting transparent, no-membership compounded GLP-1 with physician-titrated dosingStarting at $170/mo
NovoCare Pharmacy
Best for branded Wegovy at the lowest manufacturer-direct self-pay priceStarting at $149/mo
Side-by-Side Comparison
| Feature | Bon Health | NovoCare Pharmacy |
|---|---|---|
| Overall Score | 7.4/10 | ✓8.7/10 |
| Starting Price | $170/mo | ✓$149/mo |
| Editorial Rating | 3.7 ★ /5 | ✓4.4 ★ /5 |
| Features | ✓7 features | 5 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Bon Health
What we like
- Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
- Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
- 24/7 physician support included free with your order; 1-3 day rapid dispatch
- Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered
Watch-outs
- Best rates require a 6- or 12-month commitment ($170-195/mo); month-to-month is $330/mo
- Doesn't name its specific compounding pharmacy
- No legal entity name or LegitScript certification shown on the site
- Compounded GLP-1s are not FDA-approved (the site discloses this)
NovoCare Pharmacy
What we like
- First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
- $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
- $349/mo standard self-pay is well below the ~$1,300/mo retail list price
- Ships to all 50 states with no telehealth-platform middleman fees
- Cold-chain logistics handled directly by Novo Nordisk
- Insurance-billing path available via the NovoCare savings program
- NEW $149/mo Wegovy pill (oral semaglutide tablets, 1.5/4 mg) self-pay tier — 4 mg rises to $199/mo after 8/31/2026
Watch-outs
- Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
- Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
- No clinical support included — your own prescriber handles titration and side effects
- Manufacturer-set pricing can change at any time
- $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Our Verdict
NovoCare Pharmacy edges out Bon Health with a higher overall score of 8.7/10 and is particularly strong for branded Wegovy at the lowest manufacturer-direct self-pay price. Bon Health remains a solid alternative, especially if you're looking for shoppers wanting transparent, no-membership compounded GLP-1 with physician-titrated dosing.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Bon Health and NovoCare Pharmacy head-to-heads in the same category.
- Bon Health vs CoreAge Rx
- Bon Health vs TrimRx
- Bon Health vs Amazon One Medical
- NovoCare Pharmacy vs Vytora Health
- NovoCare Pharmacy vs Enhance MD
- NovoCare Pharmacy vs Noom Med
Or see the full category ranking.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.